| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John M McPartlan. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system. Brain research. Brain research reviews. vol 45. issue 1. 2004-06-28. PMID:15063097. |
the endocannabinoid system consists of two cannabinoid (cb) receptors, seven ligands, and ligand-catabolizing enzymes such as fatty acid amid hydrolase (faah) and monoglyceride lipase (mgl). |
2004-06-28 |
2023-08-12 |
Not clear |
| John M McPartlan. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system. Brain research. Brain research reviews. vol 45. issue 1. 2004-06-28. PMID:15063097. |
from an evolutionary perspective it appears that (1) endocannabinoid ligands evolved before cb receptors; (2) the ligands evolved independently multiple times; (3) cb receptors evolved prior to the metazoan-bilaterian divergence (ie, between extant hydra and leech), but were secondarily lost in the ecdysozoa; (4) vr1 may predate cb receptors but its affinity for endocannabinoids is a recent acquisition, appearing after the lower vertebrate-mammal divergence; (5) mgl may be as old as the ligands, whereas faah evolved recently, after the appearance of vertebrates. |
2004-06-28 |
2023-08-12 |
Not clear |
| John M McPartlan. Phylogenomic and chemotaxonomic analysis of the endocannabinoid system. Brain research. Brain research reviews. vol 45. issue 1. 2004-06-28. PMID:15063097. |
linking faah, vr1, and anandamide implies a coupling among the remaining "older" parts of the endocannabinoid system, mgl, cb receptors, and 2-ag. |
2004-06-28 |
2023-08-12 |
Not clear |
| I Matias, J Chen, L De Petrocellis, T Bisogno, A Ligresti, F Fezza, A H-P Krauss, L Shi, C E Protzman, C Li, Y Liang, A L Nieves, K M Kedzie, R M Burk, V Di Marzo, D F Woodwar. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. The Journal of pharmacology and experimental therapeutics. vol 309. issue 2. 2004-06-21. PMID:14757851. |
we investigated whether prostaglandin ethanolamides (prostamides) e(2), f(2alpha), and d(2) exert some of their effects by 1) activating prostanoid receptors either per se or after conversion into the corresponding prostaglandins; 2) interacting with proteins for the inactivation of the endocannabinoid n-arachidonoylethanolamide (aea), for example fatty acid amide hydrolase (faah), thereby enhancing aea endogenous levels; or 3) activating the vanilloid receptor type-1 (trpv1). |
2004-06-21 |
2023-08-12 |
human |
| Yoffi Segall, Gary B Quistad, Daniel K Nomura, John E Casid. Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors. Bioorganic & medicinal chemistry letters. vol 13. issue 19. 2004-05-03. PMID:12951114. |
arachidonylsulfonyl derivatives as cannabinoid cb1 receptor and fatty acid amide hydrolase inhibitors. |
2004-05-03 |
2023-08-12 |
mouse |
| Yoffi Segall, Gary B Quistad, Daniel K Nomura, John E Casid. Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors. Bioorganic & medicinal chemistry letters. vol 13. issue 19. 2004-05-03. PMID:12951114. |
arachidonylsulfonyl fluoride (3), reported here for the first time, is similar in potency to its known methyl arachidonylfluorophosphonate (2) analogue as an inhibitor of mouse brain fatty acid amide hydrolase activity (ic(50) 0.1 nm) and cannabinoid cb1 agonist [3h]cp 55,940 binding (ic(50) 304-530 nm). |
2004-05-03 |
2023-08-12 |
mouse |
| Maria Grazia Cascio, Alberto Minassi, Alessia Ligresti, Giovanni Appendino, Sumner Burstein, Vincenzo Di Marz. A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochemical and biophysical research communications. vol 314. issue 1. 2004-04-19. PMID:14715265. |
nagly is a potent inhibitor of the fatty acid amide hydrolase (faah), the enzyme primarily responsible for the degradation of the endocannabinoid n-arachidonoyl-ethanolamine (anandamide), and was shown recently to elevate the blood levels of the this analgesic compound. |
2004-04-19 |
2023-08-12 |
mouse |
| Benjamin F Cravatt, Aron H Lichtma. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Current opinion in chemical biology. vol 7. issue 4. 2004-04-07. PMID:12941421. |
fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. |
2004-04-07 |
2023-08-12 |
Not clear |
| Benjamin F Cravatt, Aron H Lichtma. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Current opinion in chemical biology. vol 7. issue 4. 2004-04-07. PMID:12941421. |
the recent discoveries of anandamide, a natural lipid ligand for cb1, and an enzyme, fatty acid amide hydrolase (faah), that terminates anandamide signaling have inspired pharmacological strategies to augment endogenous cannabinoid ('endocannabinoid') activity with faah inhibitors, which might exhibit superior selectivity in their elicited behavioral effects compared with direct cb1 agonists. |
2004-04-07 |
2023-08-12 |
Not clear |
| Vincenzo Di Marz. Manipulation of the endocannabinoid system by a general anaesthetic. British journal of pharmacology. vol 139. issue 5. 2004-03-09. PMID:12839861. |
an article appearing in this issue of the british journal of pharmacology shows for the first time that the general anaesthetic propofol inhibits one of the enzymes catalysing endocannabinoid hydrolysis and inactivation, the fatty acid amide hydrolase, thereby enhancing the brain levels of anandamide and 2-arachidonoylglycerol in mouse brain. |
2004-03-09 |
2023-08-12 |
mouse |
| Sachin Patel, Eric R Wohlfeil, David J Rademacher, Erica J Carrier, LaToya J Perry, Abhijit Kundu, J R Falck, Kasem Nithipatikom, William B Campbell, Cecilia J Hillar. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. British journal of pharmacology. vol 139. issue 5. 2004-03-09. PMID:12839875. |
these data suggest that propofol activation of the endocannabinoid system, possibly via inhibition of anandamide catabolism, contributes to the sedative properties of propofol and that faah could be a novel target for anesthetic development. |
2004-03-09 |
2023-08-12 |
mouse |
| Siham El Fangour, Laurence Balas, Jean-Claude Rossi, Andrey Fedenyuk, Natalia Gretskaya, Mikhail Bobrov, Vladimir Bezuglov, Cecilia J Hillard, Thierry Duran. Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues. Bioorganic & medicinal chemistry letters. vol 13. issue 12. 2004-02-11. PMID:12781177. |
three new endocannabinoid analogues in which amide moiety was replaced either by oxomethylene group or ester moiety with simultaneous substitution of both alpha-hydrogens with methyl groups were synthesized and their abilities to interact with cb1-receptor and faah were investigated. |
2004-02-11 |
2023-08-12 |
Not clear |
| b' Paola Nieri, Rosamiria Greco, Barbara Adinolfi, Maria Cristina Breschi, Enrica Martinotti, Carla Nannetti, Adriano Podest\\xc3\\xa. CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. Naunyn-Schmiedeberg\'s archives of pharmacology. vol 368. issue 5. 2004-02-10. PMID:14566452.' |
the expression of genes encoding the cannabinoid cb(1) and cb(2) receptors and fatty acid amide hydrolase (faah) and the lipolytic activity of cannabinoid agonists were investigated in rat adipose tissue.rt-pcr studies indicated that the genes encoding cb(1) and cb(2) receptors and faah are not expressed in epididymal adipocytes. |
2004-02-10 |
2023-08-12 |
rat |
| María L López-Rodríguez, Alma Viso, Silvia Ortega-Gutiérrez, Christopher J Fowler, Gunnar Tiger, Eva de Lago, Javier Fernández-Ruiz, José A Ramo. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. European journal of medicinal chemistry. vol 38. issue 4. 2004-02-06. PMID:12750028. |
the majority of compounds studied are highly potent (ic(50)=24-0.8 micro m) and selective endocannabinoid uptake inhibitors with very low affinities for either the enzyme fatty acid amide hydrolase (ic(50)=30-113 micro m) or for cannabinoid receptor subtype 1 (cb(1)), cannabinoid receptor subtype 2 (cb(2)) and vanilloid receptor subtype 1 (vr(1)) (k(i)=1000-10000 nm). |
2004-02-06 |
2023-08-12 |
Not clear |
| Cristina Benito, Estefanía Núñez, Rosa M Tolón, Erica J Carrier, Alberto Rábano, Cecilia J Hillard, Julián Romer. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 35. 2003-12-23. PMID:14657172. |
cannabinoid cb2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in alzheimer's disease brains. |
2003-12-23 |
2023-08-12 |
human |
| Cristina Benito, Estefanía Núñez, Rosa M Tolón, Erica J Carrier, Alberto Rábano, Cecilia J Hillard, Julián Romer. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 35. 2003-12-23. PMID:14657172. |
we have studied the status of some of the components of the endocannabinoid system, fatty acid amide hydrolase and cannabinoid cb1 and cb2 receptors, in postmortem brains from patients with alzheimer's disease. |
2003-12-23 |
2023-08-12 |
human |
| Cristina Benito, Estefanía Núñez, Rosa M Tolón, Erica J Carrier, Alberto Rábano, Cecilia J Hillard, Julián Romer. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 23. issue 35. 2003-12-23. PMID:14657172. |
our results show that both fatty acid amide hydrolase and cannabinoid cb2 receptors are abundantly and selectively expressed in neuritic plaque-associated astrocytes and microglia, respectively, whereas the expression of cb1 receptors remains unchanged. |
2003-12-23 |
2023-08-12 |
human |
| Tibor Harkany, Wolfgang Härtig, Paul Berghuis, Marton B Dobszay, Yuri Zilberter, Robert H Edwards, Ken Mackie, Patrik Ernfor. Complementary distribution of type 1 cannabinoid receptors and vesicular glutamate transporter 3 in basal forebrain suggests input-specific retrograde signalling by cholinergic neurons. The European journal of neuroscience. vol 18. issue 7. 2003-12-19. PMID:14622230. |
presynaptic action of endocannabinoids is largely mediated by type 1 cannabinoid (cb1) receptors, while fatty-acid amide hydrolase (faah) is involved in inactivating some endocannabinoids postsynaptically. |
2003-12-19 |
2023-08-12 |
mouse |
| Michele K McKinney, Benjamin F Cravat. Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. The Journal of biological chemistry. vol 278. issue 39. 2003-11-17. PMID:12734197. |
fatty acid amide hydrolase (faah) is a mammalian amidase signature enzyme that inactivates neuromodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide. |
2003-11-17 |
2023-08-12 |
Not clear |
| Alessia Ligresti, Tiziana Bisogno, Isabel Matias, Luciano De Petrocellis, Maria Grazia Cascio, Vittorio Cosenza, Giuseppe D'argenio, Giuseppe Scaglione, Maurizio Bifulco, Italo Sorrentini, Vincenzo Di Marz. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. vol 125. issue 3. 2003-10-02. PMID:12949714. |
the levels of endocannabinoids, cannabinoid cb(1) and cb(2) receptors, and fatty acid amide hydrolase (faah, which catalyzes endocannabinoid hydrolysis) in colorectal carcinomas (crc), adenomatous polyps, and neighboring healthy mucosa; and (2). |
2003-10-02 |
2023-08-12 |
human |